Androgen deprivation therapy (ADT), consisting of GnRH agonists (leuprolide acetate, goserelin and triptorelin) or GnRH antagonists (degarelix and relugolix), is the treatment foundational treatment for advanced prostate cancer. This evidence concerns the gene GNRH1 and prostate cancer.